Impact of variation in patient response on model-based control of glycaemia in critically ill patients by LeCompte, A.J. et al.
     
Impact of variation in patient response on model-based control of glycaemia in 
critically ill patients 
 
Aaron J. Le Compte*, Christopher G. Pretty*, Jessica Lin**, Geoffrey M. Shaw***, 
Adrienne Lynn****, J. Geoffrey Chase* 
 
*Department of Mechanical Engineering, University of Canterbury, Christchurch, New Zealand (email: 
aaron.lecompte@canterbury.ac.nz, christopher.pretty@pg.canterbury.ac.nz, geoff.chase@canterbury.ac.nz) 
** Department of Medicine, University of Otago, Christchurch, New Zealand (email: jessica.lin@otago.ac.nz) 
***Department of Intensive Care, Christchurch Hospital, Christchurch, New Zealand (email: geoff.shaw@cdhb.govt.nz) 
****Neonatal Department, Christchurch Women’s Hospital, Christchurch, New Zealand (email: adrienne.lynn@cdhb.govt.nz) 
Abstract: Critically ill patients commonly experience stress-induced hyperglycaemia, and several studies 
have shown tight glycaemic control (TGC) can reduce patient mortality. However, tight control is often 
difficult to achieve due to conflicting drug therapies and evolving patient condition. Thus, a number of 
studies have failed to achieve TGC possibly due to use of fixed insulin dosing protocols over adaptive 
patient-specific methods. Model-based targeted glucose control can adapt insulin and dextrose 
interventions to match identified patient sensitivity. This study explores the impact on control of 
assuming patient response to insulin is constant versus time-varying. Simulated trials of glucose control 
were performed on adult and neonatal virtual patient cohorts. Results indicate assumptions of constant 
insulin sensitivity can lead to significantly increased rates of hypoglycaemia, a commonly cited issue 
preventing increased adoption of tight glycaemic control in critical care. It is clear that adaptive, patient-
specific, approaches are better able to manage inter- and intra- patient variability than typical, fixed 
protocols. 
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1. INTRODUCTION 
Critically ill patients, both adult and infant, often experience 
hyperglycaemia and high levels of resistance to insulin 
(McCowen et al., 2001). Hyperglycaemia worsens outcomes, 
increasing the risk of severe infection (Bistrian, 2001), 
myocardial infarction (Capes et al., 2000) and critical illness 
such as polyneuropathy and multiple organ failure (Van den 
Berghe et al., 2001). The occurrence of hyperglycaemia is 
associated with increased morbidity and mortality in adults. 
Glycaemia variability, and thus poor control, is also 
independently associated with increased mortality (Egi et al., 
2006). 
An increasing body of recent literature links hyperglycaemia 
in preterm neonates to worsened outcomes in a parallel of the 
adult case. Studies have demonstrated an increased risk of 
further complications such as sepsis, increased ventilator 
dependence, retinopathy of prematurity, hospital length of 
stay and mortality associated with high levels of blood 
glucose (Alaedeen et al., 2006, Hays et al., 2006, Ertl et al., 
2006). 
Hyperglycaemia as a response to the stress of critical illness 
is a common origin of this altered metabolic state in both 
adults and neonates. The counter-regulatory response to 
stress increases the level of circulating catecholamines, 
resulting in increased endogenous glucose production and 
reduced sensitivity to insulin. Hyperglycaemia in the neonate 
is unique in that in addition to manifestation as a response to 
stress, several patho-physiologies are directly related to the 
immaturity of the glucose regulatory system, including 
impaired beta-cell secretion of insulin (Mitanchez-Mokhtari 
et al., 2004), limited number of insulin-dependent tissues 
(Raney et al., 2008) and hepatic unresponsiveness to glucose 
infusions (Cowett et al., 1983). 
Tight glycaemic control has been shown to reduce mortality 
by 18 - 45% in adult patients (Chase et al., 2008, Van den 
Berghe et al., 2001). There is also evidence of significant 
reductions in the need for dialysis, bacteraemia testing and 
blood transfusions with TGC using intensive insulin therapy 
(Van den Berghe et al., 2001). All of these results point 
towards the conclusion that the control of blood glucose 
levels in adult critical care has a significant clinical impact. 
Although it is now becoming an unacceptable practice to 
allow hyperglycaemia and its associated effects (Preiser and 
Devos, 2007), moderately elevated blood glucose levels are 
tolerated or recommended (Schultz et al., 2008) because of 
the fear of hypoglycaemia and higher nursing effort 
frequently associated with TGC (Preiser and Devos, 2007). 
Model-based control may offer advantages in glucose 
regulation (Chase et al., 2006). 
In general, any glycemic control protocol must reduce 
elevated blood glucose levels with minimal hypoglycaemia, 
while accounting for inter-patient variability, conflicting drug 
  
     
 
therapies and dynamically evolving physiological condition. 
Thus, it must titrate glucose control interventions based on 
some estimate of patient metabolic state – either identified 
from data in the case of adaptive model-based control, or 
assumed constant in some form as in the case of fixed insulin 
dosing protocols. 
In this study, the effects of intra- and inter- patient variability 
in sensitivity to insulin is explored in the context of 
simulations of glucose control using a clinically validated 
glucose-insulin system model. Adaptive, model-based control 
is modified in simulation to test the relative importance of 
tracking metabolic state between patients and over time by 
instructing the controller to assume the patient response to 
insulin is constant. 
Cohorts of virtual patients, fitted from clinical retrospective 
data, are used to determine the impact of not adequately 
addressing inter- or intra-patient variability on glycaemic 
control. Clinically validated virtual trial simulations are 
performed on both adult and neonatal patients to highlight the 
potential for model-based control to better adapt to 
significantly different clinical situations. 
Many insulin therapy regimes employ fixed dosing protocols, 
or dosing schemes adjusted by patient weight or other factors 
(Beardsall et al., 2007), and thus ignore inter- and/or intra-
patient variability in metabolic response. Thus, exploring the 
relative importance of model-based control to account for 
inter- vs. intra- patient variabilities and the differences in 
variability between adults and neonates can indicate the 
mechanisms by which model-based control can provide more 
robust and safer control of glucose levels. 
2. METHODS 
2.1 Models 
Blood glucose system models clinically validated in both 
adults and neonates are used in this study (Chase et al., 
2007). The overall form of the models is presented in 
Equations (1)-(3). Major components of the model are 
displayed in Fig 1. 
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Where G(t) [mmol/L] is plasma glucose I(t) [mU/L] is 
plasma insulin, uex(t) [mU/min] is exogenous insulin input, 
basal endogenous insulin secretion is IB [mU/L/min], with kI 
representing suppression of basal insulin secretion by 
exogenous insulin. Interstitial insulin is Q(t) [mU/L], with k 
[1/min] accounting for losses and transport. Body weight and 
brain weight are denoted by mbody [kg] and mbrain [kg]. Patient 
endogenous glucose clearance and insulin sensitivity are pG 
[1/min] and SI [L/(mU.min)]. The parameter VI,frac [L/kg] is 
the insulin distribution volume per kg body weight and n 
[1/min] is the transport rate of insulin from plasma. Total 
plasma glucose input is P(t) [mmol/min], endogenous 
glucose production is PEND [mmol/kg/min] and VG,frac [L/kg] 
represents the glucose distribution volume per kg body 
weight. CNS [mmol/kg/min] captures non-insulin mediated 
glucose uptake by the central nervous system. Michaelis-
Menten functions model saturation, with αI [L/mU] for the 
saturation of plasma insulin disappearance, and αG [L/mU] 
for insulin-dependent glucose clearance saturation.  
The models are similar in structure, with modifications 
generally in parameter values to account for differences in 
adult and neonatal physiology, and to account for the number 
of kinetic studies available in the neonatal literature. Further 
details on model development (Hann et al., 2005), simulation 
(Lonergan et al., 2006) and clinical usage (Wong et al., 2006) 
are available elsewhere. 
2.2 Patient cohorts 
For this study, two cohorts are analysed: 
• Adult ICU (ICU): N = 393 patients from SPRINT with 
over 40,000 hours of data (Chase et al., 2008) 
 
Time 
    
 
 
 
Blood glucose
 
Insulin sensitivity 
 
SI fitted over this period
 
Insulin rates ‘ trialed ’ over 
this time period 
 
 
S I
 
assumed
 
for this 
period
 
Past Future 
 
Fig 2. Adaptive control methodology. 
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Fig 1. Major components of the glucose-insulin model. 
  
     
 
• Neonatal ICU (NICU): N = 25 patients and over 3,500 
hours of data (Le Compte et al., 2009) 
For each cohort, insulin sensitivity, SI, is identified hourly 
from the clinical data. A virtual patient profile is the record of 
fitted insulin sensitivity. The fit and prediction ability of the 
models is similar over both cohorts, with a median blood 
glucose fit error of 1.2% (IQR: 0.5 – 2.0%) and 2.4% (IQR: 
0.9-4.8%) for the adult and neonatal cohorts respectively. 
Blood glucose prediction errors in response to insulin and 
dextrose interventions for the adult and neonatal models are 
also similar with 5 – 10% BG errors for 1 and 2 hour forward 
windows respectively. 
2.3 Simulated trials and control methods 
Adaptive control was performed in simulation across both 
cohorts using the control methodology, as described in Fig 2, 
to mimic typical clinical usage. For adaptive control the 
insulin sensitivity parameter (SI) is fitted over the patient data 
up to the current BG measurement at each BG measurement 
and control intervention cycle. This value of insulin 
sensitivity is held constant over the prediction interval and 
Equations (1) – (3) are solved for 1 to 2 hours into the future. 
The glucose response to a range of insulin values is computed 
to determine which insulin rate would achieve control closest 
to the target BG concentration. Blood glucose targets were a 
reduction of 15% per hour, to a minimum target of 5.0 
mmol/L for adults, and 6.0 mmol/L for neonates. 
To explore the impact of variation in insulin sensitivity on 
model-based control, the real-time fitting of insulin 
sensitivity was replaced by two alternatives and compared to 
the adaptive control method, summarised in Fig 3: 
•  Per-patient constant insulin sensitivity: The median 
fitted value of insulin sensitivity for each patient is used as 
the value of SI employed by the controller in choosing insulin 
rates. This control method accounts for inter- patient, but not 
intra- patient, variability. 
• Whole-cohort constant insulin sensitivity: The median 
value of insulin sensitivity for the entire cohort is used by the 
controller for all patients. This method assumes both that all 
patients exhibit the same level of response to insulin, and that 
insulin response does not exhibit any temporal variation, 
ignoring both inter- and intra- patient effects. 
Finally, model-based control results in adults are compared to 
the simulations using the SPRINT protocol – a paper-based 
protocol designed to mimic model-based control and used 
clinically since August 2005 (Chase et al., 2008). SPRINT 
uses 1-2 hourly BG measurement and intervention intervals 
and modulates both insulin infusion rates and nutritional 
inputs for control to a 4-6 mmol/L target band. 
Retrospective dextrose input profiles and constant two-hourly 
BG measurement and control interval timing was used for the 
neonatal cohort simulations, and SPRINT nutrition and BG 
measurement protocols were used for adult simulations. 
Bolus-based insulin delivery was simulated for adults and 
infusion delivery was used for the neonates. These choices 
reflect typical clinical implementation methods.  
3. RESULTS 
Empirical density functions of fitted insulin sensitivity for 
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Fig 3. Comparison of whole-cohort constant SI, per-patient 
constant SI and adaptive control methods. 
 
Fig 4. Whole-cohort insulin sensitivity distributions for 
adults (44,386 hours) and neonates (3,567 hours). 
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neonates and adult patients are compared in Fig 4. The 
median insulin sensitivity for neonates was 0.68x10-3 
L/(mU.min), compared to 0.24x10-3 L/(mU.min) for adults, 
and these values were used for the respective whole-cohort 
constant insulin sensitivity control simulation studies. The 
5% - 95% data interval was [0.17 – 1.70]x10-3 L/(mU.min) 
for neonates and [0.06 – 0.79]x10-3 L/(mU.min) for adults. 
The distributions of hourly insulin sensitivity variation 
between adults and neonates are presented in Fig.5. NICU 
patients show significantly less intra-patient temporal 
variation in insulin sensitivity. This result, coupled with the 
wider overall cohort distribution in insulin sensitivity 
suggests that NICU patients exhibit less intra-patient 
variation and higher inter-patient variation in response to 
insulin compared to adults. This result suggests the relative 
importance of identifying per-patient response to insulin 
inputs may be different between the two cohorts. 
Table 1 presents the glycaemic control performance for 
adults in simulation of model-based control with assumptions 
placed on controller-assumed insulin sensitivity. The median 
BG concentration is similar for all versions of model-based 
control. However increased variability is evident, as shown 
by the wider inter-quartile ranges and larger geometric 
standard deviations. This increased glycaemic variability is 
shown more dramatically by deteriorating time within target 
glycaemic ranges and increases in number of measurements 
below hypoglycaemic threshold and number of patients 
experiencing hypoglycaemia. This result is also evident in 
Fig. 6, which shows similar median BG for all model-based 
controllers, with the tightest spread of BG belonging to the 
adaptive control method. The per-patient constant and cohort-
constant results exhibit flatter distributions, with significant 
hypoglycaemia. The results for SPRINT in Table 1 show 
glycaemic control performance with respect to %BG within 
the target range is superior to the per-patient constant 
controller, but less effective than the adaptive controller, 
where SPRINT achieved 51.5% within the target band 
compared to 46.6% and 60.3% for per-patient constant and 
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Fig. 6. Simulated distribution of BG (top), insulin usage 
(middle) and dextrose administration (bottom) for adults.  
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Fig. 7. Simulated distribution of blood glucose 
concentration and insulin usage for neonatal patients and 
model-based controllers. 
Table 1. Simulated control for adult patients (N=393) with variations in controller-assumed insulin sensitivity 
  Model-based control SPRINT 
  Adaptive control Per-patient constant Cohort constant 
Total hours: 48,697 hours 48,721 hours 48,759 hours 48,701 hours 
Num BG measurements: 29,202 32,641 35,036 29,376 
BG median [IQR] (mmol/L): 5.5 [4.9 - 6.6] 5.5 [4.5 - 7.3] 5.3 [4.1 - 7.6] 5.9 [5.1 - 6.9] 
BG mean (geometric) (mmol/L): 5.8 5.8 5.6 6.0 
BG SD (geometric) (mmol/L): 1.3 1.4 1.5 1.3 
%BG within 4.0 - 6.1 mmol/L 60.3 46.6 38.7 51.5 
%BG within 4.0 - 8.0 mmol/L 83.1 65.8 54.1 82.1 
%BG < 4.0 mmol/L 4.8 14.0 23.2 4.8 
%BG < 2.2 mmol/L 0.05 0.33 1.03 0.04 
Num patients < 2.2 mmol/L 11 29 67 12 
Median insulin rate [IQR] (U/hr): 5.6 [2.3 - 6.0] 4.5 [1.9 - 6.0] 4.5 [2.3 - 6.0] 3.0 [2.0 - 3.0] 
Median glucose rate [IQR] (g/hour): 5.2 [3.9 - 6.5] 5.2 [3.3 - 6.5] 5.9 [2.6 - 6.5] 5.2 [3.3 - 5.9] 
 
  
     
 
cohort constant control respectively. 
Table 2 and Fig. 7 present the results of control simulations 
on the neonatal cohort. Similar loss of control performance is 
exhibited for controllers that assume constant insulin 
sensitivity. Especially evident in Fig. 7 is that the tightest, 
most vertical BG distribution is associated with adaptive 
control, yet the opposite pattern is present for insulin rates, 
where the tightest spread of values is for the whole-cohort 
constant SI controller. Thus, the constant controllers tend to 
vary insulin rates less, allowing patient variability to flow 
through to glycaemic levels, whereas adaptive control stops 
patient variability flowing through to BG levels by varying 
insulin rates in accordance to sensitivity to insulin. 
4. DISCUSSION 
Reductions in glycaemic control performance were observed 
when using controllers that used constant assumptions for 
insulin sensitivity, and is consistent across both adult and 
neonatal cohorts. Interestingly, median BG values are similar 
for all controllers tested, and the reduction in performance 
was captured in increased glycaemic variability as measured 
by higher standard deviations, lower times in target bands, 
higher hypoglycaemia and flatter cumulative distribution 
curves. This result suggests that designing and analysing 
glycaemic control with respect to a target median level of 
glycaemia may miss important information about variability. 
The effects of low blood glucose levels are considered much 
more serious and immediate than high blood sugar levels. 
Thus, there has been a trend to aim for higher BG levels to 
avoid hypoglycaemia, whereas a more effective alternative 
method may be to use protocols that adequately account for 
variability and provide tighter control, achieving the goals of 
glucose control to within healthy physiological ranges 
without increased risk of hypoglycaemia. Importantly, it may 
be time in a glycaemic control band (eg: 4.4 – 6.1 mmol/L) 
that determines outcome, rather than a target median, as 
physiologically it is consistent, controlled glycaemic values 
that ameliorate the negative effects of hyperglycaemia. 
The adaptive controller generally fed an increased amount of 
glucose compared to non-adaptive controllers, and coupled 
this with more aggressive use of insulin. The amount of 
insulin used is a non-linear function of glucose input and 
glycaemic level, and is influenced by the insulin effect 
saturation parameter ( Gα ). This result is also tied to the 
nutrition heuristics developed for SPRINT, where lower 
glucose levels are more likely to result in increased glucose 
inputs, and may be further modified to meet clinical 
requirements for glucose administration and insulin limits. 
Insulin effect saturation is not apparent in neonates at 
physiologic levels (Farrag et al., 1997), thus increases in 
insulin usage for tighter control are less evident. 
SPRINT was designed to be a low-cost, easily implemented 
paper-based protocol that implemented model-based control. 
The practicalities of clinical use means that insulin rates are 
thus discretised to whole-unit amounts, whereas model-based 
control allows a finer degree of resolution, as well as the 
ability to capture a broader range of patient dynamics. 
However, the SPRINT design goal to emulate adaptive 
model-based control is evidenced by its superior performance 
to the constant SI versions of model-based control. 
The difference in inter- and intra-patient variability between 
critically ill adults and neonates may in part be explained by 
infant growth and development. Endogenous glucose control 
systems are still developing in preterm infants and insulin-
dependent tissues are increasing. Thus, overall resistance to 
insulin tends to decrease over time. 
Insulin sensitivity (SI) has been chosen in this study to 
quantify response to insulin as it is identifiable from 
clinically available measurements. Thus, it represents several 
physiological processes, such as suppression of endogenous 
glucose production and increase in tissue glucose uptake that 
cannot be identified separately. However, the overall 
conclusion of the requirement of accounting for patient 
response over time as a major contributor to tight glycaemic 
control stands as a result independent of the specific model 
chosen. More advanced models, if able to be identified in 
clinical-real time, can provide advantages by improving 
predictive performance, and thus control quality. 
Model-based control derives interventions from an estimate 
of patient metabolic state. This estimate may be influenced 
by errors, such as noise in BG sensors, missing patient data 
and user error, increasing the observed variability in patient 
response. Control methods need to provide a balance between 
aggressiveness in meeting glycaemic targets and robustness 
to noise and errors to maintain patient safety against 
hypoglycaemia. 
Identifying the contributing factors to variation in glycaemia 
response may be useful in optimising several aspects of 
therapy in critical care and beyond. Optimisations may focus 
on the cost of measurement and control interventions in terms 
of pump expense for ambulatory individuals, multiple daily 
injections, time required to devote to maintaining blood sugar 
levels each day for diabetic patients. Also the need to 
conserve blood volumes in neonates, as well as minimise 
Table 2. Simulated control for neonatal patients (N=25) with variations in controller-assumed insulin sensitivity 
Model-based control 
Adaptive control Per-patient constant Cohort constant 
%BG within 4.0 - 7.0 mmol/L 76.9 50.1 45.6 
%BG within 4.0 - 8.0 mmol/L 87.1 60.1 54.5 
%BG < 4.0 mmol/L 2.8 13.4 13.7 
%BG < 2.6 mmol/L 0.3 3.0 1.4 
BG median [IQR] (mmol/L) 6.1 [5.5 - 6.7] 6.2 [4.9 - 8.3] 6.2 [4.7 - 9.2] 
Median insulin rate [IQR] (U/kg/hr) 0.053 [0.031 - 0.083] 0.051 [0.034 - 0.071] 0.049 [0.028 - 0.060] 
 
  
     
 
handling to prevent excessive infant stress emphasises the 
importance of optimising the balance between clinical effort 
and safe, robust control. 
4 CONCLUSIONS 
Tight glycaemic control requires adequately addressing inter- 
and intra- patient variability. Tracking patient metabolic 
response over time and titrating interventions to estimates of 
insulin sensitivity provides significant improvements in 
control performance over fixed protocols for both adults and 
neonates. This result clearly defines the differences seen in 
several published trials in outcome glycaemia and variability 
due to these variations in patient behaviour. Hence, it 
highlights the need to better account for these variations to 
maximise the opportunity for successful TGC. 
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